AbCellera Biologics Inc
Company Profile
Business description
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
Contact
150 W 4th Avenue
VancouverBCV5Y 1G6
CANT: +1 604 559-9005
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
562
Stocks News & Analysis
stocks
Chart of the Week: BHP’s growth story faces a reality check
stocks
3 best ASX growth stocks to buy for the long term
stocks
The ASX data center stock flying under the radar
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,023.30 | 26.60 | -0.29% |
| CAC 40 | 8,382.43 | 15.58 | 0.19% |
| DAX 40 | 24,999.53 | 147.50 | -0.59% |
| Dow JONES (US) | 52,658.64 | 150.37 | 0.29% |
| FTSE 100 | 10,515.92 | 13.47 | -0.13% |
| HKSE | 25,158.35 | 477.25 | 1.93% |
| NASDAQ | 26,269.23 | 162.22 | 0.62% |
| Nikkei 225 | 66,793.78 | 1,957.73 | -2.85% |
| NZX 50 Index | 13,621.10 | 13.97 | -0.10% |
| S&P 500 | 7,572.40 | 28.81 | 0.38% |
| S&P/ASX 200 | 8,827.50 | 28.70 | -0.32% |
| SSE Composite Index | 3,923.11 | 32.47 | -0.82% |